Arythmus is an innovative biotechnology company specializing in the development of cellular and drug therapies for the treatment of cardiac fibrosis. Founded by Dr. Jean Gauthier, a cardiologist and expert in cellular therapies and regenerative medicine, Arythmus is built on a public-private partnership with the Marseille Medical Genetics laboratory (INSERM - Aix-Marseille University), headed by Prof. Puceat, along with experts in cardiology, veterinary medicine, and business. The company leverages the patent entitled “LSD1 Inhibitors for Use in the Treatment and Prevention of Fibrosis of Tissues.”
Our multidisciplinary team is committed to transforming scientific discoveries into revolutionary therapeutic solutions, aiming to reduce the impact of cardiac fibrosis on patient health. In collaboration with world-renowned researchers, Arythmus pushes the boundaries of regenerative medicine to offer more effective and personalized treatments for heart failure.
Company Details
- Employees
- 1
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Arythmus Questions
Arythmus's LinkedIn profile is https://www.linkedin.com/company/arythmus
Arythmus has
1 employees.
View email and phone details for 1
employees at Arythmus.
Arythmus's industry is
Biotechnology Research
Arythmus's top competitors are
Blink Biomedical Sas,
A5 Science,
Evodx,
Oncoage,
Laboratoires Arkopharma,
Albert Deloin,
Germe S.a.,
Biotech One,
Laboratoires M&l,
Genotech Technology Solutions Co., Ltd..
Arythmus's categories are Biotechnology Research
